learndrugs
Hematologic

Thrombocytopenia (ITP & HIT)

HIT Verified · Sep 2026

Thrombocytopenia is a platelet count below 150,000/µL in adults, arising from decreased production, increased destruction, splenic sequestration, or dilution — and the mechanism, not the number, determines the treatment.

The disorder behind the petechial rash on a child’s shins, the 4Ts score, the day-7 platelet drop that means stop the heparin, and the three separate reasons not to reach for a platelet transfusion.

What’s going wrong in the body

The normal physiology, where it fails, and why the body’s compensation backfires.

01 One number, four mechanisms — and a ladder that drives every decision

"Thrombocytopenia is characterized by a platelet count that falls below the established normal threshold, specifically 150,000/µL in adults." That is the whole definition, and it is deliberately unhelpful on its own, because a platelet count is a finding rather than a diagnosis. Everything that matters follows from two further questions: how low, and why.

How low sorts into a ladder that maps directly onto nursing decisions. Mild, 100,000 to 150,000/µL — "generally asymptomatic." Moderate, 50,000 to 100,000/µL — "may manifest symptoms, eg, easy bruising." Severe, below 50,000/µL — "can lead to bleeding during surgical procedures." Critical, below 10,000/µL — the patient is "more susceptible to spontaneous hemorrhage." Read those last two carefully, because they are routinely blurred together: below 50,000 is where procedural bleeding risk climbs, and below 10,000 is where bleeding starts happening on its own. Note what the source does not say. It sets no count at which a patient may safely proceed to surgery, and no count that obliges a transfusion — both are common inferences, and neither is source wording. Transfusion decisions in this disorder follow the mechanism, not the number, and the same chapter states that "prophylactic platelet transfusions for preoperative thrombocytopenia are not well-supported by evidence."

Why sorts into four mechanisms. Decreased production — marrow failure, drugs such as valproic acid, daptomycin and chemotherapy, radiation, chronic alcohol use, nutritional deficiency of folate, B12 or copper, viral infection, myelodysplastic syndromes, and marrow infiltration by malignancy. Increased destruction, immune — primary ITP, drug-induced immune thrombocytopenia, secondary ITP from lupus, rheumatoid arthritis, lymphoproliferative disease, hepatitis C or HIV, and heparin-induced thrombocytopenia. Increased destruction, non-immune — DIC, thrombotic microangiopathy such as TTP and HUS, mechanical heart valves, preeclampsia and HELLP, antiphospholipid syndrome. Sequestration — "approximately one-third of platelets reside in the spleen," and cirrhosis with splenic congestion pulls more of them out of circulation. Dilution — massive transfusion, fluid resuscitation, and the increased plasma volume of pregnancy.

A bone-marrow biopsy, when one is done, sorts the mechanism in a single line: normal to high megakaryocytes means increased destruction; low megakaryocytes means production failure; megaloblastic changes point to nutritional deficiency, dysplasia to myelodysplastic syndrome. And before any of this, one thing must be excluded: pseudothrombocytopenia. "Platelet clumping can occur when EDTA is used as an anticoagulant," and platelet satellitism does the same — a repeat CBC helps "rule out laboratory error." A shockingly low count in a patient with no bleeding earns a smear and a repeat draw before it earns a transfusion.

A low platelet count is a finding with five possible mechanisms — and the marrow answer separates a production problem from a destruction problem in one line.

02 ITP — antibodies that mark platelets for the spleen

Immune thrombocytopenia is defined by the American Society of Hematology, as reported by StatPearls, as "a generalized purpuric rash accompanied by a platelet count less than 100,000/μL" with a normal white-cell count and hemoglobin. Note the threshold: ITP uses 100,000/μL, not the general 150,000/μL. The characteristic laboratory picture is isolated thrombocytopenia with an otherwise normal CBC — normal white cells, normal hemoglobin and red-cell indices, and a smear showing "reduced platelet levels with normal or increased size."

The mechanism is two-sided, which is why the count can be so low. IgG autoantibodies target platelet membrane glycoproteins — specifically GP IIb/IIIa, Ib/IIa and VI — and antibody-coated platelets are "cleared faster than usual by tissue macrophages, specifically in the spleen, shortening platelet half-life." That is the destruction half, and it is why splenectomy works. The second half is that T cells attack bone-marrow megakaryocytes, so production is impaired at the same time destruction is accelerated. The patient is losing platelets faster and replacing them more slowly, simultaneously.

Age changes the disease. In children it is usually self-limited: peak incidence at ages 2 to 5 and again in adolescence, the acute form predominates and is "often prefaced by a viral infection," and "most children have a self-limiting course, typically spontaneously recovering within 3 months," with roughly 25% going on to persistent or chronic disease. In adults it is usually chronic: "the chronic form more often affects adults, and the inciting factor is usually unclear," peak incidence around age 60 and rising with age, and "spontaneous remission in adults is uncommon" at about 10%. Phases are formally defined — newly diagnosed to 3 months, persistent 3 to 12 months, chronic beyond 12 months, refractory when unresponsive to splenectomy.

The bedside distinction that matters most is dry versus wet purpura. "Dry purpura affects the skin, while wet purpura involves mucous membranes." Dry purpura is watched; wet purpura escalates — and the reason is explicit: "oral purpura and gross hematuria warrant special attention, as they may precede severe hemorrhage." The feared endpoint is intracranial hemorrhage, whose risk in newly diagnosed childhood ITP is about 0.5% and under 1% in chronic childhood disease, with "most ICH cases occur at platelet levels less than 10,000/μL." Its warning symptoms are worth memorizing: "headache, persistent vomiting, altered mental status, seizures, focal neurological findings, and recent head trauma."

03 HIT — the anticoagulant that makes clots

Heparin-induced thrombocytopenia is "a severe complication that can occur in patients exposed to any form or amount of heparin products," characterized by "a fall in platelet counts and a hypercoagulable state." There are two types, and only one matters clinically. Type I is non-immune, appears as early as day 1, is mild, and "platelet counts will spontaneously normalize even if heparin is continued." Type II is "an immune, antibody-mediated reaction" that causes "a hypercoagulable state and can lead to life-threatening complications." When clinicians say HIT, they mean type II.

The mechanism is a five-step loop, and following it explains every management rule. Step one: platelet factor 4, "stored in alpha-granules of the platelets and… released upon platelet activation," binds "to exogenous heparin with a much higher affinity than heparan." Step two: that PF4-heparin complex triggers the formation of IgG antibodies against it. Step three: the antibody, "while attached to the heparin-PF4 complex, binds to the FC receptor on the platelet surface and leads to platelet activation. Activated platelets then release pro-thrombotic substances (such as thrombin) and PF4." Step four — the loop closes: "as IgG activates more platelets, more PF4 is released forming more complexes with heparin, thus activating more platelets." The anticoagulant has become a clotting trigger. Step five — why the count falls anyway: "platelet counts fall because macrophages consume the IgG-coated platelets… Simultaneously, as platelets become activated, they aggregate, and the platelet count drops as thrombus forms."

That last sentence is the whole page in miniature. The platelets are being used up in clots, which is why the count is low and why transfusing more is the wrong move — you would be feeding the reaction. And it is why HIT causes clots, not bleeds: "HIT causes an extremely hypercoagulable state, where up to 50% of patients develop thromboembolic complications, associated with a mortality rate of up to 30%," most commonly deep vein thrombosis, pulmonary embolism, or skin necrosis, in either the venous or arterial circulation. The risk is highest within the first 10 days, but "the pro-thrombotic state persists up to 30 days after stopping heparin."

Timing is the diagnostic anchor. Standard onset is "after 5 to 14 days of receiving heparin," with the 4Ts score awarding maximum points for a "clear onset days 5-10." Rapid-onset HIT breaks that rule: "if a patient has been exposed to heparin within the last 100 days, antibodies may remain in the system, causing this reaction to manifest as soon as day one of re-exposure," with counts dropping "in as little as 12 hours." Risk runs up to 5% of heparin-exposed patients, is higher with unfractionated than low-molecular-weight heparin — because the average unfractionated molecule is "45 saccharide units long" against about 15 for LMWH, and shorter chains bind less avidly to plasma proteins and cells — and is higher in surgical patients, in women, and in the elderly. Fondaparinux "does not cause HIT, nor does it react with heparin-induced antibodies."

The heparin-induced thrombocytopenia loop: the antibody activates platelets rather than destroying them passively, so the falling count and the clotting are the same event seen twice.

04 Scoring the 4Ts — and the three reasons not to transfuse

The 4Ts score turns suspicion into a decision. Four components, each scored 0 to 2. Thrombocytopenia: 2 points for "Platelet count fall > 50% and platelet nadir ≥ 20", 1 point for a 30 to 50% fall or a nadir of 10 to 19, 0 for a fall under 30% or a nadir below 10 (× 10⁹/L). Timing of the fall: 2 points for "Clear onset days 5-10 or platelet fall ≤ 1 day (prior heparin exposure within 30 days)", 1 point for a picture consistent with but not clearly days 5 to 10, onset after day 10, or a fall within 1 day with prior exposure 30 to 100 days ago, and 0 for a fall at or before day 4 without recent exposure. Thrombosis or other sequelae: 2 points for "New thrombosis (confirmed); skin necrosis; acute systemic reaction postintravenous unfractionated heparin bolus", 1 point for progressive, recurrent or suspected thrombosis or non-necrotizing skin lesions, 0 for none. Other causes of thrombocytopenia — and note the inversion that catches people out — 2 points for "none apparent", 1 for possible, 0 for definite. You score high when there is no alternative explanation.

The bands are 0 to 3 low, 4 to 5 intermediate, 6 to 8 high probability. The action threshold is unambiguous: "all forms of heparin, including line flushes, should be immediately discontinued, and treatment with an alternative anticoagulant should be pursued in any patient who scores 4 or more." But be honest about what the score is good at. A meta-analysis of 13 studies and 3,068 patients found the negative predictive value of a low score to be 0.998, while the positive predictive value of a high score was only 0.64 and of an intermediate score just 0.14. The conclusion: "a low probability 4Ts score appears to be a robust means of excluding HIT." A low score lets you keep the heparin; a high score still needs laboratory confirmation — a PF4 ELISA, which is highly sensitive with a high negative predictive value but low specificity, followed by the serotonin release assay, "the gold standard test for confirming HIT."

And then there are the three separate reasons not to reflexively transfuse platelets. In HIT, "platelet transfusions are contraindicated during the acute phase, as transfused platelets can bind to IgG and become activated and release PF4, thus worsening the hypercoagulable state." In TTP, transfusion is "considered to be contraindicated unless major bleeding is present" because it may worsen microthrombus formation. And in thrombocytopenia generally, "prophylactic platelet transfusions for preoperative thrombocytopenia are not well-supported by evidence." Three different diseases, three different rationales, one shared conclusion: a low number is not by itself an order to transfuse.

TTP deserves its own warning, because it is the diagnosis that must not be missed. It is classically taught as a pentad of fever, hemolytic anemia, thrombocytopenia, and renal and neurologic dysfunction — but the full pentad is present in less than 5% of patients, and waiting for all five is fatal. Modern practice acts on anemia and thrombocytopenia with evidence of active hemolysis: schistocytes, raised unconjugated bilirubin, raised reticulocyte count, raised LDH. The mechanism is deficiency of ADAMTS13, the von Willebrand factor-cleaving protease, so "VWF multimers accumulate on the endothelial surface, causing platelet aggregation and eventual thrombi formation." Untreated mortality is "about 90%," and the treatment is urgent therapeutic plasma exchange, which removes both the ultra-large VWF multimers and the ADAMTS13 autoantibodies.

The 4Ts score in action — its real strength is ruling HIT out at a low score, while any score of 4 or more triggers the full five-rule response.

Causes & risk factors

Modifiable factors are teaching targets — the patient can act on them.

Primary immune thrombocytopenia (ITP) — IgG autoantibodies against platelet glycoproteins Heparin exposure of any form or amount, including flushes and heparin-coated catheters modifiable Immune drug reactions — quinine, sulfonamides, ampicillin, vancomycin, piperacillin, acetaminophen, ibuprofen, naproxen, cimetidine, glycoprotein IIb/IIIa inhibitors modifiable Dose-dependent marrow suppression — valproic acid, daptomycin, linezolid, chronic alcohol use modifiable Chemotherapy and radiation Herbal and dietary — Chinese yew, yellow dock, burdock, green tea, guarana, ginseng, quinine-containing beverages and certain herbal teas modifiable Nutritional deficiency — folate, vitamin B12, copper modifiable Viral infection — HIV, hepatitis C, Epstein-Barr virus, parvovirus, mumps, varicella, rubella, Zika Bacterial and parasitic infection — Helicobacter pylori, sepsis, Plasmodium, Babesia, tick-borne disease Autoimmune and lymphoproliferative disease — systemic lupus erythematosus, rheumatoid arthritis, chronic lymphocytic leukemia, antiphospholipid syndrome Consumptive processes — disseminated intravascular coagulation, TTP, HUS, mechanical heart valves Preeclampsia and HELLP syndrome Splenic sequestration — chronic liver disease with cirrhosis and splenic congestion Dilution — massive transfusion, fluid resuscitation, and the increased plasma volume of pregnancy Bone-marrow failure and infiltration — aplastic anemia, paroxysmal nocturnal hemoglobinuria, myelodysplastic syndromes, marrow infiltration by malignancy

Signs & symptoms

Each finding tied to the mechanism that produces it — and the triage it calls for.

No symptoms at all — a platelet count of 100,000 to 150,000/µL early Expected
Why: Mild thrombocytopenia is "generally asymptomatic," and is usually found on a blood count ordered for another reason. Management is a repeat CBC and routine monitoring, not intervention.
Easy bruising at 50,000 to 100,000/µL Expected
Why: Moderate thrombocytopenia "may manifest symptoms, eg, easy bruising" — enough platelets for ordinary hemostasis, not enough to prevent visible bruising from minor knocks.
Dry purpura — petechiae and non-palpable purpura on the skin only, classically over the shins early Expected
Why: Capillary leaks going unplugged in the dependent skin. Patients see it as tiny, flat red spots under the skin — often first on the lower legs. Dry purpura is watched, not escalated.
Wet purpura — bleeding onto mucosal surfaces: oral purpura, gum bleeding, gross hematuria Hold & notify
Why: Mucosal involvement marks a different level of risk from skin involvement. "Oral purpura and gross hematuria warrant special attention, as they may precede severe hemorrhage" — the finding is a warning, not an endpoint, which is exactly why it is reported rather than watched. Prolonged epistaxis is graded separately below, because the sources call that one severe bleeding outright.
Menorrhagia — abnormally heavy periods Hold & notify
Why: A mucosal surface that sheds monthly is an early place for a platelet defect to show. In an adolescent girl, heavy periods may be the presenting complaint of ITP rather than an incidental symptom.
Epistaxis lasting 5 to 15 minutes Hold & notify
Why: The sources set this duration explicitly as constituting severe bleeding in ITP — it converts a common nuisance into a measurable escalation trigger.
Spontaneous hemorrhage at a count below 10,000/µL late Report immediately
Why: Critical thrombocytopenia — patients are "more susceptible to spontaneous hemorrhage," meaning bleeding without any provoking injury. Note this is the 10,000 threshold, distinct from the 50,000 procedural-risk threshold.
Headache, persistent vomiting, altered mental status, seizures, or focal neurological findings Report immediately
Why: The warning symptoms of intracranial hemorrhage — the feared complication of ITP, with most cases occurring below 10,000/μL. Recent head trauma in such a patient carries the same weight as the symptoms themselves.
Gastrointestinal bleeding — hematemesis, melena, or rectal bleeding Report immediately
Why: Mucocutaneous bleeding "ranging from mild petechiae and epistaxis to severe and potentially life-threatening gastrointestinal, intracranial, or urinary tract hemorrhage." The GI tract is a large mucosal surface with no external warning sign until blood appears.
A new DVT or PE in a patient whose platelet count is falling on heparin Report immediately
Why: The counter-intuitive heart of HIT: platelets are being consumed in clots, so the low count and the thrombosis are the same event. Up to 50% of HIT patients develop thromboembolic complications, with mortality up to 30%.
Skin necrosis, or an acute systemic reaction after an intravenous heparin bolus Report immediately
Why: Both are 2-point findings on the 4Ts thrombosis criterion. Skin necrosis reflects dermal microvascular thrombosis; the acute systemic reaction is an immediate antibody-mediated event on re-exposure.
A platelet fall greater than 50%, arriving between days 5 and 14 of heparin therapy early Report immediately
Why: Two sources, two halves — worth keeping straight. The greater-than-50% fall with a nadir at or above 20 is the 4Ts thrombocytopenia criterion, a scoring band rather than a diagnostic rule; the 5-to-14-day window is the onset the HIT chapter describes, which characterises the fall qualitatively as unexplained and steady rather than by any percentage. Together they are the timing signature of immune HIT. Rapid-onset HIT breaks the rule — with heparin exposure inside the previous 100 days, counts can drop within 12 hours of re-exposure.
Anemia plus thrombocytopenia, with schistocytes on the smear Report immediately
Why: This combination names an emergency: it points to DIC, TTP, HUS, sepsis or autoimmune disease. The workup is LDH, bilirubin and reticulocyte count — and in TTP, waiting for the classic pentad is fatal, since it appears in fewer than 5% of patients.
A shockingly low count in a patient who is not bleeding at all Hold & notify
Why: Suspect pseudothrombocytopenia. EDTA-induced platelet clumping and platelet satellitism both produce spuriously low automated counts, and a repeat CBC helps "rule out laboratory error." Verify before you transfuse.

Diagnostics

Test In this disorder Normal
Complete blood count with differential and peripheral smear Always paired with a reticulocyte count and a smear. Repeat the CBC first if the count is startling and the patient is not bleeding — EDTA clumping causes pseudothrombocytopenia In ITP: isolated thrombocytopenia with a platelet count "characteristically less than 100,000/μL", normal white-cell count, hemoglobin and red-cell indices, and a smear showing "reduced platelet levels with normal or increased size" Platelets 150,000–450,000/µL (ITP uses a diagnostic cutoff of 100,000/μL)
Peripheral smear morphology The smear is the cheapest test on the page and the one most likely to change the diagnosis outright — it is how TTP and leukemia are caught in a patient who was labelled "ITP" The finding that redirects the diagnosis: schistocytes → thrombotic microangiopathy or intravascular hemolysis · hypersegmented neutrophils and macro-ovalocytes → folate, B12 or copper deficiency · teardrop cells and nucleated RBCs → marrow infiltration · immature white cells → leukemia · giant platelets → Alport or Bernard-Soulier syndrome —
Tests NOT to order in typical ITP Marrow biopsy is reserved for findings suggesting malignancy or marrow failure. ITP remains a diagnosis of exclusion made on the CBC, the smear, and targeted secondary testing Antiplatelet antibody testing "is not recommended when evaluating ITP as it does not correlate with clinical outcomes." Bone-marrow biopsy "is no longer performed for typical ITP presentations" ASH (as reported by StatPearls) —
Targeted secondary testing in ITP Interpret ANA carefully — 17.5% of patients with ITP have a positive antinuclear antibody test, so a positive result is not by itself diagnostic of secondary ITP Helicobacter pylori testing in patients "with recurrent epigastric pain suggestive of peptic ulcer"; HIV and hepatitis C screening; ANA —
4Ts score (HIT pretest probability) Score 4 or more and all heparin stops immediately, including line flushes. Its real strength is exclusion: negative predictive value of a low score is 0.998, while positive predictive value is only 0.64 at a high score and 0.14 at intermediate. Remember the inverted fourth criterion — "none apparent" scores 2 Four components scored 0–2: thrombocytopenia magnitude, timing of the fall, thrombosis or sequelae, and other causes. Bands: 0–3 low · 4–5 intermediate · 6–8 high Cuker et al., Blood 2012 (systematic review and meta-analysis) —
PF4 ELISA (heparin-PF4 immunoassay) "Highly sensitive and has a high negative predictive value" — HIT can be ruled out if this test is negative — but low specificity produces false positives. A positive ELISA needs confirmation Positive when "the optical density (OD) is greater than 0.4" — and the magnitude matters: "less than 3% of patients with an OD of 0.4-1 will have a true positive result", while an OD greater than 2 "correlates with ~ 90% chance of having HIT" —
Serotonin release assay (SRA) A functional assay: donor platelets exposed to heparin plus the patient’s IgG release serotonin. The guideline "recommends getting a confirmatory SRA for any patient with a positive ELISA" "Gold standard test for confirming HIT with high sensitivity and specificity" — a positive SRA confirms the diagnosis, and a "negative SRA rules out HIT, even in the setting of a positive ELISA" ASH 2018 (as reported by StatPearls) —
Platelet count monitoring on heparin Reported through a review that found no current evidence-based guidelines meeting its criteria, so treat this as a monitoring convention rather than current guidance. The principle it encodes still holds: the HIT window is days 5 to 14, so that is when counts are watched Monitored "every 2 or 3 days from day 4 to day 14 (or until heparin is stopped) for patients receiving heparin who are considered to have more than a 1% risk of HIT" ACCP 2012 (as reported by CADTH) —

Complications

Warning: Thromboembolism in HIT — clots, not bleeds Report immediately
Deep vein thrombosis, pulmonary embolism, or skin necrosis, in either the venous or arterial circulation, in a patient whose platelet count is falling.
"HIT causes an extremely hypercoagulable state, where up to 50% of patients develop thromboembolic complications, associated with a mortality rate of up to 30%." Risk is highest in the first 10 days, but the prothrombotic state "persists up to 30 days after stopping heparin" — which is why isolated HIT without thrombosis still earns about a month of anticoagulation.
Warning: Intracranial hemorrhage Report immediately
Headache, persistent vomiting, altered mental status, seizures, focal neurological findings, or recent head trauma in a severely thrombocytopenic patient.
The feared complication of ITP — about 0.5% in newly diagnosed children and under 1% in chronic childhood disease, with "most ICH cases occur at platelet levels less than 10,000/μL." Named risk factors are extremely low counts, head trauma, antiplatelet medication use, and severe bleeding. Head trauma at a count below 10,000/μL is the dominant risk factor and is treated as an emergency even if the patient looks well.
Warning: Warfarin-associated skin necrosis and venous limb gangrene Report immediately
The iatrogenic complication of starting warfarin during acute HIT.
"When warfarin is first initiated, the natural anticoagulants, protein C and S, whose synthesis is vitamin K-dependent, will be depleted first, while the vitamin-K-dependent clotting factors remain in circulation, leading to a hypercoagulable state." Started during acute HIT, "protein C and S depletion can severely worsen coagulation and increase the risk of thromboembolic complications, particularly skin necrosis." If warfarin was already running, it is held and vitamin K given to replete protein C and S stores.
Warning: Thrombotic thrombocytopenic purpura — the diagnosis that must not be missed Report immediately
Anemia and thrombocytopenia with schistocytes, raised LDH, raised unconjugated bilirubin and raised reticulocytes — with or without neurologic change.
The classic pentad appears in fewer than 5% of patients, so waiting for fever, anemia, thrombocytopenia, renal and neurologic dysfunction together is fatal. Untreated mortality is "about 90%." The mechanism is ADAMTS13 deficiency letting VWF multimers accumulate and aggregate platelets. Treatment is urgent therapeutic plasma exchange, and when TTP and HUS overlap, "it is better to place the patient initially on plasma exchange" because TTP carries the higher immediate mortality.
Caution: Harm from treating the number instead of the mechanism
Platelet transfusion is contraindicated in acute HIT and avoided in TTP, and prophylactic transfusion before procedures is poorly supported generally.
In HIT, "transfused platelets can bind to IgG and become activated and release PF4, thus worsening the hypercoagulable state." In TTP, transfusion is "contraindicated unless major bleeding is present" because it may worsen microthrombus formation. And broadly, "prophylactic platelet transfusions for preoperative thrombocytopenia are not well-supported by evidence." In paediatric chronic ITP the same principle holds in a different form: "most mortality and morbidity… result from complications of long-term immunosuppressive treatment, mainly infections" — the treatment, not the count.

Medications for this condition

Why each class is prescribed here — every card links to its full pharmacology page.

Corticosteroids First-line
Endocrine · prednisone

First-line for ITP, and with a treatment threshold rather than a reflex. Per the ASH ITP guidelines (2019 thresholds, unchanged in the 2026 update), corticosteroids are recommended for adults with newly diagnosed ITP and a platelet count below 30,000/μL who are asymptomatic or have only minor mucocutaneous bleeding — and for counts at or above 30,000/μL, "observation instead" is advised. That single pair of numbers prevents a great deal of unnecessary immunosuppression. They work by inhibiting autoantibody production and platelet destruction, the same two arms the disease attacks through. The disorder-side caution is duration: prednisone "for an extended duration exceeding 6 weeks" is not recommended, because in chronic paediatric ITP most mortality and morbidity come from the complications of long-term immunosuppression rather than from the platelet count. The 2026 ASH update keeps that threshold and the 6-week limit but now suggests pairing the initial corticosteroid with rituximab or a thrombopoietic agent (± IVIG) where available, rather than giving corticosteroids alone. Steroids are often paired with intravenous immunoglobulin, which is "often considered to have an augmentative effect."
Anticoagulants High-alert
Cardiovascular · heparin

This class appears here as the cause, not the cure. Heparin in any form or amount can trigger HIT — including flushes, heparin-coated catheters and heparin in dialysate — and unfractionated heparin carries more risk than low-molecular-weight heparin because its longer saccharide chains bind plasma proteins and cells more readily. Fondaparinux "does not cause HIT, nor does it react with heparin-induced antibodies." When HIT is diagnosed, the response is not simply to stop: all heparin stops and a non-heparin anticoagulant starts immediately, because the prothrombotic state persists up to 30 days. Two further rules belong to this class. Warfarin must not be started until the platelet count has recovered — ideally to at least 150,000/µL or the patient’s baseline — and only after a non-heparin agent has overlapped for at least 5 days, or protein C and S depletion precipitates skin necrosis. And in ITP, anticoagulants are avoided altogether when the platelet count is below 20,000/μL.

Beyond medications

  • Verify before you treat. A repeat CBC with a smear excludes pseudothrombocytopenia from EDTA-induced clumping or platelet satellitism. For asymptomatic mild thrombocytopenia, "repeat CBC and routine monitoring is the recommended management" — no drug, no transfusion.
  • Stop the offending drug. In drug-induced thrombocytopenia, discontinuing the agent is the management and recovery typically follows. Screen against the named lists: immune causes such as quinine, sulfonamides, ampicillin, vancomycin, piperacillin, acetaminophen, ibuprofen, naproxen, cimetidine and glycoprotein IIb/IIIa inhibitors; and dose-dependent marrow suppressants such as valproic acid, daptomycin, linezolid and chronic alcohol.
  • The five HIT rules, in order. (1) Stop every source of heparin — "including heparin flushes, heparin-coated catheters, and heparin in the dialysate." (2) Start a non-heparin anticoagulant immediately — per the 2018 ASH guideline as reported by StatPearls, argatroban, bivalirudin, danaparoid, fondaparinux or a direct oral anticoagulant, at therapeutic intensity for a high 4Ts score. (3) Do not transfuse platelets. (4) Do not start warfarin until the count recovers and a non-heparin agent has overlapped 5 days. (5) Anticoagulate long enough — about 1 month for isolated HIT, since the prothrombotic state persists up to 30 days, and 3 months if thrombosis is present.
  • The 100-day rule for future heparin exposure. "Following an episode of HIT, IgG antibodies may remain in the system for up to 100 days (median of 85 days); if the patient receives any amount of unfractionated or low-molecular-weight heparin during this period, platelet counts can drop in as little as 12 hours. If this 100-day period has passed, heparin products can be used with caution if necessary, at the lowest dose and for the least amount of time possible."
  • ITP second- and later-line options (plain text, no class links here): intravenous immunoglobulin for urgent or severe bleeding and when corticosteroids are contraindicated; anti-D immunoglobulin, which carries an FDA boxed warning for intravascular hemolysis in ITP, including deaths; thrombopoietin receptor agonists — romiplostim and eltrombopag responding in 7 to 14 days, avatrombopag in 3 to 5, with the practical note that eltrombopag absorption is reduced by calcium-rich foods while avatrombopag does not interact with dairy; rituximab, contraindicated in hepatitis B; and fostamatinib for refractory disease. Since the COVID-19 pandemic, practice has shifted "from immunosuppressants and splenectomy to second-generation thrombopoietin receptor agonists." For patients who still need treatment after initial corticosteroids, the 2026 ASH update recommends a thrombopoietic agent or suggests rituximab; for those who cannot have either, a BTK inhibitor, mycophenolate, or the SYK inhibitor fostamatinib.
  • Splenectomy is deliberately delayed — in children "at least 12 months from initial diagnosis and until the child is older than 5," and in adults "until a year after ITP diagnosis due to the potential for remission within that time frame" — and the 2026 ASH second-line recommendations name thrombopoietic agents and rituximab, addressing splenectomy only in a good-practice statement. It works because antibody-coated platelets are cleared mainly in the spleen.
  • Secondary ITP is treated by treating the cause — Helicobacter pylori eradication, immunosuppressants for lupus, antiviral therapy for hepatitis C or HIV. Monitoring cadence: "platelets should be monitored a week after a dose or drug change and every month once the patient’s condition stabilizes."

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Assessment & monitoring
Take the history that changes management: recent medications and supplements, heparin exposure in any hospitalized patient, infectious exposures and travel, prior blood counts — and the rate of decline, not just the current value.
Why: The rate of fall is what separates a stable chronic low count from an evolving consumptive process, and heparin exposure is the one question that turns a falling count into a diagnosis with a five-step protocol attached.
Inspect skin and mucosa every shift for "petechiae, non-palpable purpura, and ecchymosis" — and classify what you find as dry or wet.
Why: Dry purpura is skin only and is watched; wet purpura is mucosal and escalates, because "oral purpura and gross hematuria warrant special attention, as they may precede severe hemorrhage." The distinction, not the rash itself, is the nursing judgement.
Keep the three platelet thresholds in separate lanes: below 50,000 is procedural bleeding risk, below 20,000 is an ITP major-bleeding risk factor and the point anticoagulants are avoided, below 10,000 is spontaneous hemorrhage. None of the three is by itself a transfusion order.
Why: These numbers are routinely merged into a vague "10 to 20 thousand" band, which loses the distinction between bleeding during a procedure and bleeding without provocation. Each threshold answers a different question.
On heparin, watch the platelet count from day 4 through day 14, and treat a fall of more than 50% as a HIT question until proven otherwise.
Why: The immune HIT window is 5 to 14 days, classically 5 to 10. The conventional monitoring cadence is every 2 to 3 days across that window for patients with more than a 1% risk — and rapid-onset HIT can drop counts within 12 hours if there was heparin exposure inside the last 100 days.
In any thrombocytopenic patient on heparin, assess for clots as actively as for bleeding: unilateral leg swelling, sudden dyspnea or pleuritic chest pain, new skin necrosis, cold or dusky extremities.
Why: HIT causes clots, not bleeds — up to 50% develop thromboembolic complications with mortality up to 30%. A nurse watching only for bruising will miss the actual danger entirely.
Repeat the CBC with a smear before acting on a startling count in a patient who is not bleeding.
Why: EDTA-induced platelet clumping and platelet satellitism produce pseudothrombocytopenia, and a repeat CBC helps "rule out laboratory error." The smear also catches the findings that change the diagnosis outright — schistocytes, blasts, teardrop cells.
Interventions & safety
When the 4Ts score reaches 4 or more, ensure every source of heparin stops — infusions, subcutaneous doses, line flushes, heparin-coated catheters, and heparin in dialysate.
Why: The instruction is explicit and includes the sources most easily overlooked. A patient can remain exposed through a flush protocol long after the infusion is stopped, and any exposure keeps the antibody-driven loop running.
Do not transfuse platelets in HIT, and expect them to be withheld in TTP unless there is major bleeding.
Why: In HIT "transfused platelets can bind to IgG and become activated and release PF4, thus worsening the hypercoagulable state" — you would be feeding the reaction. In TTP transfusion may worsen microthrombus formation. A low number is not an order to transfuse.
Question any warfarin order in acute HIT, and confirm both criteria before it starts: platelet recovery to at least 150,000/µL or baseline, and at least 5 days of overlap with a non-heparin anticoagulant.
Why: Warfarin depletes protein C and S before the clotting factors fall, producing a transient hypercoagulable state. Started during acute HIT it "can severely worsen coagulation… particularly skin necrosis." If it was already started, it is held and vitamin K given.
Apply the sourced bleeding precautions: soft-bristled toothbrush, home injury-prevention measures, and contact-sport restriction keyed to the count — caution above 50,000/µL, avoid contact sports entirely below 10,000/µL, caution in between.
Why: These are the precautions the sources actually support. Note that "avoid intramuscular injections" and "avoid rectal temperatures," though widely taught here, are not sourced for thrombocytopenia — they belong to neutropenia, a different precaution for a different reason.
Screen out and teach against platelet-function inhibitors by name: aspirin, NSAIDs, ginkgo biloba, and quinine-containing beverages and herbal teas.
Why: These add a functional platelet defect to a quantitative one, and antiplatelet medication use is a named risk factor for intracranial hemorrhage in ITP. Every prescription and over-the-counter product is reviewed with the clinician.
Escalate to hematology immediately for HIT, TTP, HUS, drug-induced ITP, severe thrombocytopenia with bleeding, aplastic anemia or leukemia — and for any urgent procedure at a severe count.
Why: These are the named call-now conditions. TTP in particular is untreatable by waiting: untreated mortality is about 90%, the classic pentad appears in fewer than 5% of patients, and the treatment is urgent plasma exchange.
Patient & family teaching
For ITP, teach the activity restriction that matches the count — below 30,000/μL, avoid contact and collision sports such as football, boxing, lacrosse and hockey, and any activity with significant head-injury risk including baseball, soccer, skiing and gymnastics.
Why: This is the ASH-aligned restriction as reported by StatPearls, and it is specific for a reason: head trauma at a very low count is the dominant risk factor for intracranial hemorrhage, the complication that defines the ceiling of risk in ITP.
Teach what to report: petechiae, unexplained bruising, or mucosal bleeding — and separately neurologic changes, chest pain, or leg swelling.
Why: The same patient may need to report both a bleed and a clot. A family primed to watch only for blood will miss the thrombotic half of HIT or antiphospholipid syndrome entirely.
Teach the escalation rule plainly: bleeding that will not stop, or a headache, repeated vomiting, confusion or a seizure, means emergency care now — and treat any head injury or new severe headache as an emergency at a low count.
Why: Its simplicity is the point — it requires no judgement about how much blood is too much. The head-injury rule is added because intracranial hemorrhage announces itself through headache, vomiting, altered mental status, seizures or focal findings rather than through visible blood.
After an episode of HIT, teach the 100-day rule rather than calling it an allergy: antibodies persist for up to 100 days, any heparin inside that window can drop the count within 12 hours, and afterward heparin may be used with caution at the lowest dose for the shortest time.
Why: No fetched source describes documenting HIT as a "heparin allergy," but all of them describe the antibody timeline and the avoidance it demands. The 100-day rule is more accurate and more actionable — it tells the patient what changes and when.
Set expectations by age in ITP: most children recover within 3 to 6 months, while adults rarely remit spontaneously — about 10% — and most need ongoing drug therapy.
Why: Families of children need reassurance that watchful waiting is a plan rather than neglect; adults need to understand that this is usually a long-term condition. "Patients and their families must be educated about the diagnosis of ITP, associated bleeding risks, proper treatment, and the importance of therapeutic compliance."
Counsel women of childbearing age about pregnancy risks, and teach pregnant patients to seek urgent evaluation for headache, vision changes or abdominal pain.
Why: Those three symptoms point to preeclampsia and HELLP syndrome, a consumptive cause of thrombocytopenia that needs obstetric and maternal-fetal medicine involvement rather than hematology alone.

How a real nurse thinks

The clinical-judgment loop, worked for a typical presentation — reasoning, not reference.

  1. 1
    Recognize cues

    The cues that matter are a falling platelet count and a new clot arriving together, in a patient on heparin, on postoperative day 7. The count has fallen from 240 to 95 × 10⁹/L — a 60% fall with a nadir comfortably above 20 — and it has fallen steadily rather than fluctuating. Equally important is what is absent: no petechiae, no purpura, no bruising, no bleeding from the wound or mucosa, a stable hemoglobin, no new drugs, no infection. The thing most likely to go wrong here is reading the low platelet count as a bleeding problem and the DVT as an unrelated surgical complication. They are the same event.

  2. 2
    Analyze cues

    Score the 4Ts. Thrombocytopenia: a fall greater than 50% with a nadir at or above 20 scores 2. Timing: clear onset on day 7, squarely inside days 5 to 10, scores 2. Thrombosis: a new confirmed thrombosis scores 2. Other causes: none apparent — no sepsis, no new drug, no dilution — and remember the scoring here is inverted, so "none apparent" scores 2. Total 8, which falls in the 6 to 8 high-probability band. She is also in two named higher-risk groups: surgical patients have more platelet activation and PF4 release from mechanical injury, and unfractionated heparin carries more risk than low-molecular-weight heparin because its longer saccharide chains bind plasma proteins and cells more readily. Hold the score with appropriate humility — the positive predictive value of a high score is only 0.64 — but a high score still demands the full response while laboratory confirmation is pending.

  3. 3
    Prioritize

    The priority is not the clot and not the platelet count — it is the heparin. Every hour she remains exposed, the antibody-driven loop keeps activating platelets and generating thrombin, and the prothrombotic state that already produced one DVT keeps running. So priority one is stopping all heparin. Priority two is starting a non-heparin anticoagulant, because simply stopping is insufficient: the prothrombotic state persists up to 30 days after heparin is withdrawn, and up to 50% of HIT patients develop thromboembolic complications with mortality up to 30%. Priority three is laboratory confirmation, which follows rather than precedes treatment. And running underneath all of it is a decision to not do two things that would feel natural: transfuse platelets, and start warfarin.

  4. 4
    Generate solutions

    Hold the ordered heparin increase and raise the concern immediately — this order would escalate the exposure that is causing the problem. Ensure all heparin stops, including the line flushes and any heparin-coated catheter, not just the subcutaneous doses. Anticipate a non-heparin anticoagulant at therapeutic intensity, since the 4Ts score is in the high band: argatroban, bivalirudin, danaparoid, fondaparinux or a direct oral anticoagulant per the 2018 ASH guidance as reported by StatPearls. If argatroban is chosen, expect a continuous infusion without a bolus titrated to an aPTT of 1.5 to 3 times baseline, with a lower starting rate in hepatic dysfunction or heart failure, and be ready for it to raise the INR profoundly, which matters later when bridging. Send a PF4 ELISA, with a confirmatory serotonin release assay if it is positive. Plan for 3 months of anticoagulation because thrombosis is present.

  5. 5
    Take action

    Act, then call. Stop the heparin, remove heparin flushes from her orders, and do not give the increased dose. Then escalate with the reasoning made explicit: "POD 7 right total hip on prophylactic unfractionated heparin. Platelets have fallen from 240 to 95 — a 60% drop — with a clear day-7 onset, a newly confirmed right femoral DVT, and no other apparent cause. That is a 4Ts score of 8, high probability. I have held the heparin increase and stopped all heparin including line flushes. Requesting a non-heparin anticoagulant at therapeutic intensity, and a PF4 ELISA with SRA confirmation." Three traps to name explicitly. Increasing the heparin is the intuitive response to a new DVT and is exactly wrong here. Transfusing platelets for a count of 95 would feed the reaction, since transfused platelets bind IgG, activate, and release more PF4. And starting warfarin now would deplete protein C and S first and risk skin necrosis — warfarin waits until the count recovers to at least 150,000/µL or baseline and a non-heparin agent has overlapped for at least 5 days.

  6. 6
    Evaluate

    Success over the coming days: no new thrombosis, the platelet count recovering back toward her 240 baseline, therapeutic anticoagulation maintained on the non-heparin agent, and laboratory confirmation returned. Watch for the complications that would signal the loop is still running — extension of the DVT, symptoms of pulmonary embolism, new skin necrosis at injection sites, or cold and dusky extremities. Before discharge, the teaching is specific and it is not "you are allergic to heparin": antibodies persist for up to 100 days, median 85, any heparin inside that window can drop her count within 12 hours, and after 100 days heparin may be used with caution at the lowest dose for the shortest possible time. The counter-intuitive summary she should leave with is the same one that organizes this whole page: her platelet count was low, and the danger was clotting.

Scenario — you’re the nurse

Work each question before revealing the answer. Rationales explain the wrong options too.

Orthopedic surgical unit · 1000, postoperative day 7

A 68-year-old woman, postoperative day 7 after right total hip arthroplasty, on prophylactic unfractionated heparin subcutaneously since surgery. She has no history of bleeding disorders and had no heparin exposure in the previous year. Overnight she developed right calf swelling and pain; a duplex ultrasound this morning has confirmed a new right femoral deep vein thrombosis. The surgical team has asked you to prepare to increase her heparin to a therapeutic dose.

1000 vitals — HR 92 · BP 138/78 · RR 18 · SpO₂ 96% on room air · T 37.0 °C
Platelet trend — admission 240 · POD 3 232 · POD 5 178 · POD 7 95 × 10⁹/L (a 60% fall from baseline)
Assessment — right calf swollen, warm, tender · no petechiae, no purpura, no bruising, no mucosal or wound bleeding · surgical incision dry and intact
Imaging — duplex ultrasound confirms new right femoral DVT
Chart — prophylactic subcutaneous unfractionated heparin since POD 0 · heparin line flushes per unit protocol · hemoglobin stable · no new drugs started · no infection · creatinine normal
Q1 Multiple choice
Calculate this patient’s 4Ts score — platelets fell 240 to 95 × 10⁹/L, clear onset on day 7, new confirmed DVT, no other apparent cause — and identify the probability band.
  1. A. Score 4 — intermediate probability
  2. B. Score 6 — high probability
  3. C. Score 8 — high probability
  4. D. Score 5 — intermediate probability
Reveal answer & rationale
Answer: C
Each component scores the maximum. Thrombocytopenia: a fall greater than 50% (60%) with a nadir at or above 20 × 10⁹/L scores 2. Timing: a clear onset on day 7 falls within days 5 to 10 and scores 2. Thrombosis: a new confirmed thrombosis scores 2. Other causes: "none apparent" scores 2 — this is the inverted criterion that catches people out, since you score highest when there is no alternative explanation. Total 8, in the 6 to 8 high-probability band (C). Options (A), (B) and (D) all undercount, most often by scoring the fourth T as though "no other cause" meant zero points. Whatever the total, remember the action threshold sits lower: any score of 4 or more means all heparin stops immediately.
Q2 Multiple choice
The surgical team has ordered an increase to therapeutic heparin for the new DVT. What should the nurse do?
  1. A. Administer the increased dose, since a confirmed DVT requires therapeutic anticoagulation
  2. B. Hold the dose, ensure all heparin including line flushes is stopped, and escalate the 4Ts score and concern for HIT
  3. C. Administer the dose but request a platelet transfusion first to cover the low count
  4. D. Hold all anticoagulation entirely until the PF4 ELISA result returns
Reveal answer & rationale
Answer: B
This is heparin-induced thrombocytopenia until proven otherwise, and the drug causing it must stop — all forms, including line flushes — with escalation for a non-heparin anticoagulant (B). (A) escalates the exposure driving the antibody loop; the DVT does need therapeutic anticoagulation, but not with heparin. (C) compounds two errors: it continues the heparin and adds a platelet transfusion, which in acute HIT is contraindicated because "transfused platelets can bind to IgG and become activated and release PF4, thus worsening the hypercoagulable state." (D) is the subtler trap — simply stopping is not enough, because the prothrombotic state "persists up to 30 days after stopping heparin" and up to 50% of patients develop thromboembolic complications. A non-heparin agent starts immediately, before laboratory confirmation returns.
Q3 Select all that apply
Which statements about this patient’s management are correct? Select all that apply.
  1. A. Warfarin should not be started until the platelet count recovers and a non-heparin anticoagulant has overlapped for at least 5 days
  2. B. Because thrombosis is present, about 3 months of anticoagulation is anticipated
  3. C. A platelet transfusion is indicated because the count has fallen by more than 50%
  4. D. A negative serotonin release assay would rule out HIT even if the PF4 ELISA were positive
  5. E. Fondaparinux does not cause HIT and does not react with heparin-induced antibodies
Reveal answer & rationale
Answer: A, B, D, E
Warfarin is deferred (A) because it depletes protein C and S before the clotting factors, risking skin necrosis in acute HIT — the criteria are platelet recovery to at least 150,000/µL or baseline and a 5-day overlap. Three months is the sourced duration when thrombosis is present (B), against about one month for isolated HIT. A negative SRA "rules out HIT, even in the setting of a positive ELISA" (D), since the ELISA is sensitive but poorly specific. And fondaparinux "does not cause HIT, nor does it react with heparin-induced antibodies" (E). Only (C) is wrong, and it is the most tempting: platelet transfusion is contraindicated in acute HIT, because transfused platelets bind IgG, activate, and release more PF4 — feeding the reaction. Her platelets are low because they are being consumed in clots, not because she is bleeding.
Q4 Multiple choice
Before discharge the patient asks whether she should now be listed as allergic to heparin. The best response is:
  1. A. "Yes — heparin should be documented as an allergy so you never receive it again."
  2. B. "The antibodies persist up to about 100 days, so heparin must be avoided during that window because your count could drop within 12 hours. After 100 days it can be used with caution at the lowest dose for the shortest time."
  3. C. "No — once your platelet count recovers, heparin is safe again at any dose."
  4. D. "It does not matter, since low-molecular-weight heparin is safe for anyone who has had HIT."
Reveal answer & rationale
Answer: B
The sourced framing is an antibody timeline rather than an allergy label (B): IgG antibodies "may remain in the system for up to 100 days (median of 85 days)," any unfractionated or low-molecular-weight heparin within that period can drop counts "in as little as 12 hours," and afterward "heparin products can be used with caution if necessary, at the lowest dose and for the least amount of time possible." (A) is not supported by any source and is also less useful — it tells the patient nothing about when the risk changes. (C) ignores the antibody persistence entirely and would permit re-exposure during the highest-risk window. (D) is dangerous: LMWH carries lower risk than unfractionated heparin but still causes HIT and still reacts with the antibodies. The agent that genuinely does not is fondaparinux.
Q5 Put in order
A different patient — a 5-year-old, well, two weeks after a viral illness, with a pinpoint petechial rash over both shins, an otherwise normal CBC apart from platelets of 18,000/µL, and a normal smear apart from large platelets. Put the appropriate actions in priority order:
  1. A. Arrange hematology follow-up with a monitoring plan and family teaching on activity restriction
  2. B. Assess specifically for wet purpura and for headache, vomiting, altered mental status or recent head trauma
  3. C. Confirm the count is real — review the smear and consider a repeat CBC to exclude pseudothrombocytopenia
  4. D. Teach the family to avoid aspirin, NSAIDs and ginkgo, and to seek emergency care for severe bleeding or head injury
Reveal answer & rationale
Correct order: B → C → A → D
Assess for danger first (B): the distinction between dry purpura, which is watched, and wet purpura, which escalates, changes management immediately — and the intracranial-hemorrhage warning signs of headache, persistent vomiting, altered mental status, seizures, focal findings or recent head trauma matter most at counts below 10,000/μL. Then verify the number (C), since EDTA clumping causes pseudothrombocytopenia and the smear also rules out the findings that would redirect the diagnosis, such as blasts or schistocytes. Follow-up and the monitoring plan come next (A) — this child fits the typical picture, where most recover spontaneously within 3 months, antiplatelet antibody testing is not recommended, and marrow biopsy "is no longer performed for typical ITP presentations." Medication and emergency teaching (D) is essential but is the reinforcement layer, not the first action at the bedside.

Common questions

What causes thrombocytopenia (itp & hit)?
Common causes and risk factors include primary immune thrombocytopenia (itp) — igg autoantibodies against platelet glycoproteins, heparin exposure of any form or amount, including flushes and heparin-coated catheters, immune drug reactions — quinine, sulfonamides, ampicillin, vancomycin, piperacillin, acetaminophen, ibuprofen, naproxen, cimetidine, glycoprotein iib/iiia inhibitors, dose-dependent marrow suppression — valproic acid, daptomycin, linezolid, chronic alcohol use, chemotherapy and radiation, and others.
What are the early signs of thrombocytopenia (itp & hit)?
Early findings include No symptoms at all — a platelet count of 100,000 to 150,000/µL, Dry purpura — petechiae and non-palpable purpura on the skin only, classically over the shins, A platelet fall greater than 50%, arriving between days 5 and 14 of heparin therapy.
Which findings should a nurse report immediately in thrombocytopenia (itp & hit)?
Report immediately: Spontaneous hemorrhage at a count below 10,000/µL, Headache, persistent vomiting, altered mental status, seizures, or focal neurological findings, Gastrointestinal bleeding — hematemesis, melena, or rectal bleeding, A new DVT or PE in a patient whose platelet count is falling on heparin, Skin necrosis, or an acute systemic reaction after an intravenous heparin bolus, and others. These signal deterioration that needs rapid intervention.
At what platelet count does bleeding actually start?
It depends which kind of bleeding you mean, and the thresholds are routinely merged into one vague band. Below 50,000/µL is where bleeding becomes a risk during surgical procedures. Below 10,000/µL is where patients become "more susceptible to spontaneous hemorrhage" — bleeding without any provoking injury. Resist turning either into a transfusion rule: no source gives a count that requires transfusion support, and the same chapter says "prophylactic platelet transfusions for preoperative thrombocytopenia are not well-supported by evidence." A separate 20,000 figure exists but belongs to two other rules: it is a named risk factor for major bleeding in ITP, and it is the count below which anticoagulants are avoided. Keep all three in their own lanes. Between 50,000 and 100,000/µL patients "may manifest symptoms, eg, easy bruising," and between 100,000 and 150,000/µL they are generally asymptomatic.
Why does heparin-induced thrombocytopenia cause clots instead of bleeding?
Because the platelets are being used up in clots rather than destroyed passively. The antibody against the heparin-PF4 complex binds the FC receptor on the platelet surface and activates it, so the platelet releases thrombin and more PF4 — which forms more complexes and activates more platelets, closing a self-amplifying loop. Activated platelets then aggregate, "and the platelet count drops as thrombus forms." The result is that "HIT causes an extremely hypercoagulable state, where up to 50% of patients develop thromboembolic complications, associated with a mortality rate of up to 30%," most often DVT, pulmonary embolism, or skin necrosis. The same mechanism explains why platelet transfusion is contraindicated in acute HIT: transfused platelets bind IgG, activate, and release still more PF4, feeding the reaction.
Is a platelet transfusion the obvious answer to a very low count?
Often not, and there are three separate reasons to pause. In HIT, transfusion is contraindicated during the acute phase because transfused platelets are activated by the same antibody and worsen the hypercoagulable state. In TTP, it is "contraindicated unless major bleeding is present," because it may worsen microthrombus formation. And in thrombocytopenia generally, "prophylactic platelet transfusions for preoperative thrombocytopenia are not well-supported by evidence." There is also a fourth, more mundane reason: pseudothrombocytopenia from EDTA-induced platelet clumping or platelet satellitism produces spuriously low automated counts, so a repeat CBC helps "rule out laboratory error." A startling count in a patient who is not bleeding earns a smear and a repeat draw before it earns a transfusion.

Sources

Reviewed by Hae Suk Lee, RN

Educational summary for nursing students. Scenarios are fictional teaching cases. Always verify against current guidelines and your institution's protocols before acting in practice. Not medical advice.

Bookmark LearnDrugs.com?

Your saved pages are kept in this browser. Add LearnDrugs.com to your browser’s bookmarks to get back to them in one click.

Drag this link to your bookmarks bar: LearnDrugs.com

Or press Ctrl + D to bookmark the page you’re on.